<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131896</url>
  </required_header>
  <id_info>
    <org_study_id>rmc7800ctil</org_study_id>
    <nct_id>NCT02131896</nct_id>
  </id_info>
  <brief_title>The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes</brief_title>
  <official_title>The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nutritional therapy has a major role in diabetes care, achieving and maintaining metabolic&#xD;
      control: normal glucose homeostasis, normal lipid profile, normal blood pressure and&#xD;
      desirable weight. Controlled nutritional diet, as introduced by the professional committees&#xD;
      aims at achieving better general health condition.&#xD;
&#xD;
      There is a growing body of evidence showing that Mediterranean diet has a major role in&#xD;
      prevention of diabetes sequelae in type 2 diabetes patients. Hitherto, the effects of&#xD;
      Mediterranean diet on patients with type 1 diabetes has not been studied, with the exception&#xD;
      of one Italian study.&#xD;
&#xD;
      Six months after education to consume Mediterranean diet in a cohort of 96 children with type&#xD;
      1 diabetes the authors observed decreased fat and cholesterol consumption, increased dietary&#xD;
      fiber consumption, lower LDL cholesterol levels and better HDL to LDL cholesterol ratio.&#xD;
&#xD;
      The proposed study is aimed to assess the impact of Mediterranean nutrition compared to the&#xD;
      accepted nutritional guidelines, in newly diagnosed type 1 children and adolescents on lipid&#xD;
      profile, metabolic control, C peptide, daily insulin dose, Inflammatory parameters,&#xD;
      endothelial function and anthropometric parameters 12 months following diagnosis.&#xD;
&#xD;
      The study designed as a two parallel arms, randomized, single center, intervention study.&#xD;
&#xD;
      Patients enrolled to the study will be randomly assigned, to one of the following groups in a&#xD;
      1:1 ratio. Interventional Arm: Patients assigned to the interventional arm will receive&#xD;
      nutritional instructions of Mediterranean diet and Control Group: Patients assigned to the&#xD;
      interventional arm will receive regular nutritional instructions in accordance with the&#xD;
      accepted nutritional guidelines&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lipid profile</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
    <description>fasting blood lipid profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
    <description>Metabolic control expressed as HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean and SD of blood glucose</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
    <description>Metabolic control expressed as mean and SD of downloaded blood glucose values from patient's personal glucometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak stimulated C peptide</measure>
    <time_frame>At the end of the study- after 12 months</time_frame>
    <description>Peak stimulated C peptide &gt; o.2 pmol/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily insulin dose</measure>
    <time_frame>At the end of the study- after 12 months</time_frame>
    <description>Daily insulin dose adjusted for body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who require a daily insulin dose &lt; o,5 IU/kg</measure>
    <time_frame>At the end of the study- after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hypoglycemic episodes</measure>
    <time_frame>At the end of the study- after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric parameters</measure>
    <time_frame>At the end of the study- after 12 months</time_frame>
    <description>Anthropometric parameters: Body weight ,BMI SDS, body composition and weight change from diagnosis to 12 months after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change from at least 1 year before diagnosis to 12 months after diagnosis</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
    <description>Inflammatory parameters: TNF, CRP, IL-6, fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>At the end of the study-after 12 months</time_frame>
    <description>Endothelial function: Doppler assessment of the tunica intima</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mediterranean Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular nutritional instructions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular nutritional instructions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interventional arm-Mediterranean diet</intervention_name>
    <arm_group_label>Mediterranean Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines</intervention_name>
    <arm_group_label>Regular nutritional instructions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parents/guardian are willing and able to sign an informed consent form&#xD;
&#xD;
          -  Age 5-18 years&#xD;
&#xD;
          -  Diagnosis with type 1 diabetes for up to 2 months prior to screening&#xD;
&#xD;
          -  Peak C peptide &gt; o.2 pmol/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has any significant disease or conditions, including psychiatric disorders&#xD;
             that in the opinion of the principal investigator might interfere with patient's&#xD;
             compliance or ability to complete the study&#xD;
&#xD;
          -  Any concomitant disease that might impact body composition, physical activity level&#xD;
             and/or eating habits&#xD;
&#xD;
          -  Active celiac disease, hashimoto thyroiditis or uncontrolled Graves' disease&#xD;
&#xD;
          -  Down syndrome, Turner, inflammatory bowel disease&#xD;
&#xD;
          -  Patients treated with antipsychotic drugs, steroids, or other drugs that might affect&#xD;
             body weight and appetite.&#xD;
&#xD;
          -  Patient who suffers from eating disorders&#xD;
&#xD;
          -  Patients participating in other device or drug studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liat de Vries, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Newly diagnosed</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Mediterranean diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

